Heterocyclic Cannabinoid Receptor Modulators for Selective Pain Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cannabinoid receptor-mediated disorders, such as neuropathic pain and addiction, lack effective pharmaceutical solutions that specifically target CB1 and CB2 receptors without causing psychoactive effects.
Innovation Solution
Development of novel heterocyclic compounds that modulate CB1 and CB2 receptor activity, defined by specific structural formulas, which are used in pharmaceutical compositions to treat these disorders by administering a therapeutically effective amount of the compounds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cannabinoid receptor treatments are used, then therapeutic effects are achieved, but psychoactive effects are caused
Solution Approach 1:
The patent applies local quality by developing compounds with specific heterocyclic structures (Formula I and Formula II) that selectively modulate CB1 and CB2 receptors in particular tissue locations. The compounds are designed to target specific receptor subtypes in different organs (e.g., peripheral CB2 receptors for pain management without affecting central CB1 receptors that mediate psychoactive effects), thereby achieving therapeutic effects while avoiding psychoactive side effects through localized receptor engagement.
2Reliability
If CB1 and CB2 receptor modulators are developed, then specific therapeutic targeting is achieved, but compound complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the cannabinoid receptor modulation strategy into two distinct compound series (Formula I and Formula II), each targeting different receptor profiles. Formula I compounds are designed for CB1 modulation while Formula II compounds target CB2 receptors. This segmentation allows for optimized structural features in each series tailored to their specific receptor targets, managing complexity through systematic classification while achieving high receptor selectivity.
Solution Approach 2:
The patent applies parameter changes by systematically varying heterocyclic ring structures, substituent groups, and molecular configurations in the compound formulas to optimize receptor binding affinity and selectivity. By adjusting parameters such as heteroatom positioning, substituent types, and molecular size, the compounds achieve high receptor specificity without excessive structural complexity, balancing therapeutic targeting with synthesizability.
Data Source
AI summary
Heterocyclic compounds which modulate cannabinoid receptors are presented. Pharmaceutical compositions containing these compounds, methods of using these compounds as modulators of cannabinoid receptors and processes for synthesizing these compounds are also described herein.